Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
Cancer treatment reviews. 2017 Sep 01 [Epub ahead of print]
Amparo Sánchez-Gastaldo, Emmanuelle Kempf, Aránzazu González Del Alba, Ignacio Duran
Medical Oncology Department, Hospital Universitario "Virgen del Rocio", Seville, Spain., Medical Oncology Department, Hôpital Universitaire Henri Mondor - Albert Chenevier, AP-HP, Créteil, France., Medical Oncology Department, Hospital Universitario "Son Espasses", Palma de Mallorca, Spain., Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. Electronic address: .